Skip to content
HowShorted

Protara Therapeutics, Inc. short interest in 2023

In 2023, Protara Therapeutics, Inc.'s disclosed short interest ran from 0.75% of shares outstanding on 13 Jan 2023 to 0.64% on 29 Dec 2023, a change of -0.11 percentage points. The year's high was 0.96% on 15 Jun 2023 and its low 0.41% on 15 Aug 2023, averaging 0.65% across 24 twice-monthly settlement dates. FINRA's days-to-cover figure peaked at 9.30 days on 31 Jan 2023. Full history: Protara Therapeutics, Inc..

Cite this page
Plain
Wikipedia
BibTeX

By year: 2019 · 2020 · 2021 · 2022 · 2023 · 2024 · 2025 · 2026

Aggregate net short position time series for Protara Therapeutics, Inc. in 2023

2023 in figures

Start of year
0.75% (13 Jan 2023)
End of year
0.64% (29 Dec 2023)
Change
-0.11 pp
High
0.96% (15 Jun 2023)
Low
0.41% (15 Aug 2023)
Average
0.65%
Highest days to cover
9.30 (31 Jan 2023)
SEC filings marked
8

Every report in 2023

Protara Therapeutics, Inc. short interest in 2023
SettlementShort interestDays to coverFilings since previous
13 Jan 20230.75%5.96
31 Jan 20230.75%9.30
15 Feb 20230.73%3.86
28 Feb 20230.69%3.78
15 Mar 20230.68%2.3110-K filed, results (8-K)
31 Mar 20230.68%1.97
14 Apr 20230.67%3.75
28 Apr 20230.90%1.55
15 May 20230.86%4.2110-Q filed, results (8-K)
31 May 20230.86%2.35
15 Jun 20230.96%4.39
30 Jun 20230.87%2.38
14 Jul 20230.96%3.34
31 Jul 20230.69%2.04
15 Aug 20230.41%1.4210-Q filed, results (8-K)
31 Aug 20230.46%6.11
15 Sep 20230.43%2.95
29 Sep 20230.45%3.55
13 Oct 20230.43%2.56
31 Oct 20230.42%1.02
15 Nov 20230.43%1.0010-Q filed, results (8-K)
30 Nov 20230.52%1.05
15 Dec 20230.44%1.00
29 Dec 20230.64%1.25

See also: Protara Therapeutics, Inc.'s full history · most shorted US stocks of 2023 · today's US league.

About this data

US short interest data: FINRA (finra.org), shown as reported shares short divided by SEC-reported shares outstanding for each settlement date. FINRA® is a registered trademark of the Financial Industry Regulatory Authority, Inc. This site is not affiliated with or endorsed by FINRA or the SEC; displayed for personal reference, bulk redistribution is not permitted (see terms). Nothing here is investment advice. Method: methodology.